DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 19-537/S-080
NDA 19-847/S-052
NDA 19-857/S-059
NDA 20-780/S-038
NDA 21-473/S-033

SUPPLEMENT APPROVAL

Bayer Pharmaceuticals Inc.
Attention: Larry Winick
Deputy Director, Global Regulatory Affairs
P.O. Box 1000
Montville, New Jersey 07045-1000

Dear Mr. Winick:

Please refer to your supplemental New Drug Applications (sNDAs), dated August 10, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for

NDA 19-537 Ciprofloxacin Tablets
NDA 19-847 Ciprofloxacin IV for Inusion Vial
NDA 19-857 Ciprofloxacin 0.2 % Solution in 5% Dextrose
NDA 20-780 Ciprofloxacin Oral Suspension
NDA 21-473 Cipro XR Tablets

These "Prior Approval" supplemental new drug applications provide for revisions to the label as provided in our correspondence dated June 24, 2011.

Under **WARNINGS, Central Nervous System Effects/ Disorders** subsection, include pseudotumor cerebri as noted below:

"Increased intracranial pressure (including pseudotumor cerebri)"

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending

"Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Fariba Izadi, Pharm.D., Regulatory Project Manager, at (301) 796-0563.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Deputy Director for Safety
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE(S):
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
10/18/2011